Skip to main content
Home
FULL MENU Close Menu
Home
Home

Jeff Evans

Jeff Evans has been editor of Rheumatology News/MDedge Rheumatology and the EULAR Congress News since 2013. He started at Frontline Medical Communications in 2001 and was a reporter for 8 years before serving as editor of Clinical Neurology News and World Neurology, and briefly as editor of GI & Hepatology News. He graduated cum laude from Cornell University (New York) with a BA in biological sciences, concentrating in neurobiology and behavior.

News

Rheumatology workforce shortage demands multipronged approach

Author:
Jeff Evans
Publish date: December 16, 2022

Members of the American College of Rheumatology’s Workforce Solutions Committee described a multitude of ways in which the society aims to marshal...

  • Read More

News

Intensive gout treatment meets urate goal, lowers tophi burden

Author:
Jeff Evans
Publish date: November 18, 2022

A randomized trial of therapy to intensively lower urate for patients with gout showed benefits in meeting serum urate goal, tophus size, and...

  • Read More

News

FDA approves upadacitinib (Rinvoq) for sixth indication

Author:
Jeff Evans
Publish date: October 24, 2022

Upadacitinib’s approval for nonradiographic axial spondyloarthritis marks the sixth indication in the United States for the Janus kinase inhibitor...

  • Read More

News

Analysis of PsA guidelines reveals much room for improvement on conflicts of interest

Author:
Jeff Evans
Publish date: October 6, 2022

Researchers show that a majority of the authors of the most recent psoriatic arthritis clinical practice guidelines from the American College of...

  • Read More

News

FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form

Author:
Jeff Evans
Publish date: August 17, 2022

The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.

  • Read More

News

Ustekinumab becomes second biologic approved for PsA in kids

Author:
Jeff Evans
Publish date: August 3, 2022

The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to...

  • Read More

News

Rheumatology awards from ACR, EULAR, and BSR reveal gender gap

Author:
Jeff Evans
Publish date: July 29, 2022

The number of female prize winners has increased over the past 2 decades to nearly equal that of male winners, but the most prestigious prizes are...

  • Read More

News

Upadacitinib recommended for nonradiographic axSpA in Europe

Author:
Jeff Evans
Publish date: June 28, 2022

The Janus kinase inhibitor is already approved for active ankylosing spondylitis in the European Union.

  • Read More

News

Osteoporosis risk rises with air pollution levels

Author:
Jeff Evans
Publish date: June 21, 2022

Chronic exposure to particulate matter 2.5 mcm or larger in size at concentrations above 25 mcg per cubic meter raised the likelihood of...

  • Read More

News

FDA adds RA indication for Riabni rituximab biosimilar

Author:
Jeff Evans
Publish date: June 8, 2022

Riabni is the second rituximab biosimilar to be approved for rheumatoid arthritis in the United States.

  • Read More

News

Secukinumab’s antipsoriatic effects confirmed in U.S. patient population

Author:
Jeff Evans
Publish date: April 25, 2022

Results from a postmarketing trial conducted solely at U.S. centers found similar, albeit lower, responses to secukinumab 300 mg than was noted in...

  • Read More

News

Orphenadrine recalled due to possible nitrosamine impurity

Author:
Jeff Evans
Publish date: March 24, 2022

The voluntary recall of Orphenadrine Citrate 100 mg Extended Release Tablets by Sandoz involves 13 lots of the drug that were shipped to consumers...

  • Read More

News

Rheumatologist convicted of fraudulently billing millions of dollars in services

Author:
Jeff Evans
Publish date: March 16, 2022

Alice Chu, MD, is 1 of 48 people who were charged in 2019 as part of a larger enforcement action involving more...

  • Read More

News

Rheumatology News celebrates 20 years

Author:
Jeff Evans
Publish date: February 1, 2022

Rheumatology News’ first issue was published in February 2002, and in 2022 we’ll be taking a look back at rheumatology’s past and ahead to its...

  • Read More

News

Lilly calls it quits on baricitinib’s development for lupus

Author:
Jeff Evans
Publish date: January 28, 2022

The company said it is stopping phase 3 trials because of disappointing results.

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close